Ongoing Clinical Trials for AMD at Casey Eye Institute
Gene Therapy for Wet AMD (GEM Study)
Purpose: To evaluate the safety and dosing levels of a gene-based treatment, RetinoStat®, for wet AMD. In this study, two helpful genes are delivered directly to the retina, where they "turn on" proteins that block abnormal blood vessel growth in a sustained fashion. Enrollment is completed and study patients are being followed.
Contact: Ann Lundquist, 503 494-6364
Genetics of Age-Related Macular Degeneration Study
Purpose: To find genetic mechanisms associated with AMD, which will lead to more accurate early detection and precise treatments. Researchers are using advanced whole genome sequencing technology to find gene variations in large families and other populations affected by AMD. The study, supported by a major grant from the National Eye Institute, is being carried out in partnership with genetic statisticians at the Texas Biomedical Research Institute in San Antonio, Texas, as well as other collaborators in the U.S. and elsewhere.
Contact: Jennifer Maykoski, 503 494-3064
Purpose: To test the capabilities of high-speed optical coherence tomography (OCT) in patients with dry or wet AMD. OCT uses light waves to produce extremely detailed cross-sectional images of eye structures. Investigators are studying whether this new version of OCT can visualize and measure blood vessel growth as well as fluorescein angiography, which involves the injection of a contrasting agent to highlight the problem vessels. The team is also comparing how retinal anatomy and blood flow differ among study patients in early, intermediate and advanced dry AMD.
SEATTLE Study (For Dry AMD)
Purpose: To learn if an oral study medication, emixustat hydrocholoride, slows progression to advanced dry AMD (geographic atrophy) compared to placebo in people with dry AMD. Enrollment is completed and study patients are being followed.
Contact: Shelley Hanel, 503 494-1986
On the Horizon
The Macular Degeneration Center expects to launch several clinical trials of experimental medications in the near future. More details will be available in the coming months. For more information about our research activities, please contact the program coordinator at 503 494-3537.